Eli Lilly paid CSL $100 million upfront to license rights to clazakizumab, an IL‑6 monoclonal antibody, in indications outside CSL’s retained program. CSL will keep rights for a Phase 3 program testing clazakizumab to prevent cardiovascular events in end‑stage kidney disease; Lilly will pursue other inflammatory and immunologic indications. The agreement includes undisclosed milestones and royalties. The move expands Lilly’s inflammatory portfolio into IL‑6 biology and mirrors broader industry interest in targeting cytokine pathways for diverse immune-mediated diseases.